We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
+25.82%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$11.2M
(+6.5%)
Cap. Flow
+$16.6M
Cap. Flow
% of AUM
9.07%
Top 10 Holdings %
Top 10 Hldgs %
33.05%
Holding
110
New
26
Increased
27
Reduced
30
Closed
19
Avg Time Held Equity + Options
0.7
quarters
Top 10 Avg Time Held Equity + Options
0.4
quarters
Top 20 Avg Time Held Equity + Options
0.5
quarters
Avg Time Held Equity only
0.7
quarters
Top 10 Avg Time Held Equity only
0.4
quarters
Top 20 Avg Time Held Equity only
0.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$9.45M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$6.59M |
| 3 |
Merus
MRUS
|
+$5.65M |
| 4 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
+$5.12M |
| 5 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
+$4.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vericel Corp
VCEL
|
+$7.21M |
| 2 |
ESSA Pharma
EPIX
|
+$5.8M |
| 3 |
Delcath Systems
DCTH
|
+$5.74M |
| 4 |
Sutro Biopharma
STRO
|
+$4.02M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$2.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.04% |
| 2 | Miscellaneous | 4.89% |
| 3 | Financials | 3.11% |
| 4 | Industrials | 0.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Aclaris Therapeutics
ACRS
$503M
| $8.49M | 4.63% |
+336,737
| New | +$6.59M |
2021 Q1
0 quarters
|
|
2
Curis
CRIS
$1.46M
| $7.12M | 3.88% |
1,572
+247
| +19% | +$1.03M |
2020 Q4
1 quarter
|
|
|
3
Vericel Corp
VCEL
$2.05B
| $6.78M | 3.7% |
122,125
-159,221
| -57% | -$7.21M |
2020 Q4
1 quarter
|
|
4
Insmed
INSM
$21B
| $6.5M | 3.54% |
190,810
+15,810
| +9% | +$604K |
2020 Q4
1 quarter
|
|
|
AMYT
5
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $5.99M | 3.27% |
429,863
+27,307
| +7% | +$382K |
2020 Q4
1 quarter
|
|
6
DELISTED
Immunogen Inc
IMGN
| $5.91M | 3.22% |
729,364
+129,364
| +22% | +$1.06M |
2020 Q4
1 quarter
|
|
|
RACB
7
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $5.13M | 2.8% |
+500,000
| New | +$5.12M |
2021 Q1
0 quarters
|
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.11M | 2.79% |
200,000
-27,388
| -12% | -$700K |
2020 Q4
1 quarter
|
|
|
9
DELISTED
Merus
MRUS
| $5.11M | 2.79% |
+244,713
| New | +$5.65M |
2021 Q1
0 quarters
|
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.46M | 2.43% |
48,476
+18,476
| +62% | +$1.56M |
2020 Q4
1 quarter
|
|
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.42M | 2.41% |
130,117
-69,883
| -35% | -$2.42M |
2020 Q4
1 quarter
|
|
12
Halozyme
HALO
$13.2B
| $4.38M | 2.39% |
104,945
+4,945
| +5% | +$226K |
2020 Q4
1 quarter
|
|
|
MSACU
13
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
| $4.01M | 2.19% |
+406,791
| New | +$4.14M |
2021 Q1
0 quarters
|
|
14
DELISTED
Affimed
AFMD
| $3.97M | 2.17% |
50,233
+10,233
| +26% | +$664K |
2020 Q4
1 quarter
|
|
15
Aldeyra Therapeutics
ALDX
$52.2M
| $3.82M | 2.09% |
+321,879
| New | +$3.71M |
2021 Q1
0 quarters
|
|
16
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.8M | 2.07% |
60,000
+8,567
| +17% | +$393K |
2020 Q4
1 quarter
|
|
|
JNCE
17
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $3.6M | 1.96% |
350,000
-56,665
| -14% | -$621K |
2020 Q4
1 quarter
|
|
|
RNLX
18
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $3.45M | 1.88% |
134,555
-6,698
| -5% | -$168K |
2020 Q4
1 quarter
|
|
|
TCRR
19
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $3.43M | 1.87% |
155,145
+19,145
| +14% | +$522K |
2020 Q4
1 quarter
|
|
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.42M | 1.87% |
50,089
+33,589
| +204% | +$2.72M |
2020 Q4
1 quarter
|
|
21
Veracyte
VCYT
$3.51B
| $3.23M | 1.76% |
+60,000
| New | +$3.46M |
2021 Q1
0 quarters
|
|
22
EyePoint Inc
EYPT
$260M
| $3.05M | 1.66% |
+300,000
| New | +$3.38M |
2021 Q1
0 quarters
|
|
23
Verastem
VSTM
$795M
| $2.96M | 1.61% |
99,791
+5,145
| +5% | +$144K |
2020 Q4
1 quarter
|
|
24
Decoy Therapeutics
DCOY
$806K
| $2.95M | 1.61% |
+55
| New | +$3.15M |
2021 Q1
0 quarters
|
|
25
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.87M | 1.56% |
55,974
+2,208
| +4% | +$133K |
2020 Q4
1 quarter
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Silverarc Capital Management held 110 positions worth $183M, up 6.5% from $172M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Silverarc Capital Management deployed $16.6M of net new capital in Q1 2021, opening 26 new positions and adding to 27 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Vericel Corp, an estimated $7.21M trimmed.
- Silverarc Capital Management's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
- Silverarc Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021, an estimated $2.72M increase.
- Silverarc Capital Management's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $7.21M.
- Silverarc Capital Management fully exited Sutro Biopharma in Q1 2021, selling an estimated $4.02M.
- Silverarc Capital Management's ten largest holdings make up 33% of its $183M portfolio in Q1 2021.
- Silverarc Capital Management opened 26 new positions and closed 19 in Q1 2021.
- Silverarc Capital Management's portfolio value rose 6.5% quarter-over-quarter to $183M.
Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.